NCT06991348

Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole

Multicenter, Active-controlled, Randomized, Double-blind, Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole: TOP-GERD

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 128 (estimated)
• Sponsor: Carnot Laboratories · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this clinical trial is to compare which of the two drugs best resolves symptoms in patients diagnosed with erosive and non-erosive gastroesophageal reflux disease, adult males and females. The main question is What is the proportion of patients with resolution of the main symptoms of gastroesophageal reflux disease at four weeks of treatment with pantoprazole vs tegoprazan.

Conditions

• Gastroesophageal Reflux Disease

Interventions

Type	Name	Description
DRUG	Tegoprazan	Tegoprazan 50 mg daily for 28 days
DRUG	Pantoprazole	Pantoprazole 40 mg daily for 28 days

Timeline

• Start date: 2024-07-30
• Primary completion: 2025-11-30
• Completion: 2025-11-30
• First posted: 2025-05-27
• Last updated: 2025-07-23

Locations

2 sites across 1 country: Mexico